Does the media prefer HCWB or TVRD?

In the previous week, HCW Biologics had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 2 mentions for HCW Biologics and 1 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 1.08 beat HCW Biologics' score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tvardi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend HCWB or PLRZ?

HCW Biologics presently has a consensus target price of $30.00, suggesting a potential upside of 930.93%. Given HCW Biologics' stronger consensus rating and higher possible upside, equities analysts clearly believe HCW Biologics is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, HCWB or PLRZ?

Polyrizon has lower revenue, but higher earnings than HCW Biologics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HCW Biologics $50K 93.12 -$7.96M -$56.75 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is HCWB or PLRZ more profitable?

Polyrizon has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Polyrizon's return on equity of 0.00% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets HCW Biologics -34.73% -486.87% -29.19% Polyrizon N/A N/A N/A

Does the media prefer HCWB or PLRZ?

In the previous week, HCW Biologics had 1 more articles in the media than Polyrizon. MarketBeat recorded 2 mentions for HCW Biologics and 1 mentions for Polyrizon. Polyrizon's average media sentiment score of 0.75 beat HCW Biologics' score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Polyrizon 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EVAX or HCWB more profitable?

Evaxion A/S has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Evaxion A/S's return on equity of -73.56% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% HCW Biologics -34.73% -486.87% -29.19%

Does the media favor EVAX or HCWB?

In the previous week, HCW Biologics had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 2 mentions for HCW Biologics and 1 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 0.00 equaled HCW Biologics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HCW Biologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer HCWB or VYNE?

HCW Biologics currently has a consensus price target of $30.00, indicating a potential upside of 930.93%. Given HCW Biologics' stronger consensus rating and higher possible upside, analysts plainly believe HCW Biologics is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Does the media prefer HCWB or VYNE?

In the previous week, VYNE Therapeutics had 2 more articles in the media than HCW Biologics. MarketBeat recorded 4 mentions for VYNE Therapeutics and 2 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 0.00 beat VYNE Therapeutics' score of -0.30 indicating that HCW Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VYNE Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

HCW Biologics (HCWB) Competitors

$2.91 -0.44 (-13.13%)

As of 11:48 AM Eastern

Compare

HCWB vs. TVRD, PLRZ, BRNS, EVAX, and VYNE

Should you buy HCW Biologics stock or one of its competitors? MarketBeat compares HCW Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HCW Biologics include Tvardi Therapeutics (TVRD), Polyrizon (PLRZ), Barinthus Biotherapeutics (BRNS), Evaxion A/S (EVAX), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical products" industry.

How does HCW Biologics compare to Tvardi Therapeutics?

HCW Biologics (NASDAQ:HCWB) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

HCW Biologics has higher earnings, but lower revenue than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	93.12	-$7.96M	-$56.75	N/A
Tvardi Therapeutics	$7.14M	3.34	-$18.21M	-$3.10	N/A

HCW Biologics currently has a consensus target price of $30.00, suggesting a potential upside of 930.93%. Tvardi Therapeutics has a consensus target price of $19.67, suggesting a potential upside of 674.58%. Given HCW Biologics' higher possible upside, equities analysts plainly believe HCW Biologics is more favorable than Tvardi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, HCW Biologics had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 2 mentions for HCW Biologics and 1 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 1.08 beat HCW Biologics' score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tvardi Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tvardi Therapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Tvardi Therapeutics' return on equity of -64.17% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 9.1% of HCW Biologics shares are held by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

HCW Biologics has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

Summary

Tvardi Therapeutics beats HCW Biologics on 9 of the 17 factors compared between the two stocks.

How does HCW Biologics compare to Polyrizon?

HCW Biologics (NASDAQ:HCWB) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

In the previous week, HCW Biologics had 1 more articles in the media than Polyrizon. MarketBeat recorded 2 mentions for HCW Biologics and 1 mentions for Polyrizon. Polyrizon's average media sentiment score of 0.75 beat HCW Biologics' score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Polyrizon	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Polyrizon has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Polyrizon's return on equity of 0.00% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Polyrizon	N/A	N/A	N/A

HCW Biologics presently has a consensus target price of $30.00, suggesting a potential upside of 930.93%. Given HCW Biologics' stronger consensus rating and higher possible upside, equities analysts clearly believe HCW Biologics is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.0% of HCW Biologics shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Polyrizon has lower revenue, but higher earnings than HCW Biologics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	93.12	-$7.96M	-$56.75	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

HCW Biologics has a beta of 2.29, indicating that its share price is 129% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.59, indicating that its share price is 259% less volatile than the broader market.

Summary

HCW Biologics beats Polyrizon on 8 of the 13 factors compared between the two stocks.

How does HCW Biologics compare to Barinthus Biotherapeutics?

HCW Biologics (NASDAQ:HCWB) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 9.1% of HCW Biologics shares are held by company insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

HCW Biologics has higher earnings, but lower revenue than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	93.12	-$7.96M	-$56.75	N/A
Barinthus Biotherapeutics	$14.97M	1.66	-$66.43M	-$1.29	N/A

HCW Biologics currently has a consensus target price of $30.00, indicating a potential upside of 930.93%. Barinthus Biotherapeutics has a consensus target price of $4.00, indicating a potential upside of 555.74%. Given HCW Biologics' higher possible upside, equities research analysts plainly believe HCW Biologics is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, HCW Biologics had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 2 mentions for HCW Biologics and 0 mentions for Barinthus Biotherapeutics. HCW Biologics' average media sentiment score of 0.00 equaled Barinthus Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
HCW Biologics	Neutral
Barinthus Biotherapeutics	Neutral

HCW Biologics has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.41, indicating that its stock price is 141% less volatile than the broader market.

Barinthus Biotherapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Barinthus Biotherapeutics' return on equity of -63.83% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

Summary

HCW Biologics beats Barinthus Biotherapeutics on 8 of the 13 factors compared between the two stocks.

How does HCW Biologics compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

In the previous week, HCW Biologics had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 2 mentions for HCW Biologics and 1 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 0.00 equaled HCW Biologics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HCW Biologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evaxion A/S has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Evaxion A/S's return on equity of -73.56% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
HCW Biologics	-34.73%	-486.87%	-29.19%

Evaxion A/S currently has a consensus target price of $11.00, suggesting a potential upside of 261.84%. HCW Biologics has a consensus target price of $30.00, suggesting a potential upside of 930.93%. Given HCW Biologics' higher possible upside, analysts clearly believe HCW Biologics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Evaxion A/S has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market.

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 9.1% of HCW Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Evaxion A/S has higher revenue and earnings than HCW Biologics. Evaxion A/S is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.37	-$7.71M	-$1.47	N/A
HCW Biologics	$50K	93.12	-$7.96M	-$56.75	N/A

Summary

Evaxion A/S beats HCW Biologics on 9 of the 15 factors compared between the two stocks.

How does HCW Biologics compare to VYNE Therapeutics?

HCW Biologics (NASDAQ:HCWB) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, VYNE Therapeutics had 2 more articles in the media than HCW Biologics. MarketBeat recorded 4 mentions for VYNE Therapeutics and 2 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 0.00 beat VYNE Therapeutics' score of -0.30 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VYNE Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 9.1% of HCW Biologics shares are held by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

HCW Biologics has a beta of 2.29, suggesting that its share price is 129% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

HCW Biologics currently has a consensus price target of $30.00, indicating a potential upside of 930.93%. Given HCW Biologics' stronger consensus rating and higher possible upside, analysts plainly believe HCW Biologics is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

HCW Biologics has a net margin of -34.73% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

HCW Biologics has higher earnings, but lower revenue than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	93.12	-$7.96M	-$56.75	N/A
VYNE Therapeutics	$570K	52.00	-$26.48M	-$0.38	N/A

Summary

HCW Biologics beats VYNE Therapeutics on 11 of the 16 factors compared between the two stocks.

Get HCW Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCWB vs. The Competition

Export

Metric	HCW Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.73M	$3.66B	$6.84B	$12.26B
Dividend Yield	N/A	2.18%	2.67%	9.42%
P/E Ratio	-0.05	21.44	26.79	23.82
Price / Sales	93.12	304.57	578.59	114.47
Price / Cash	N/A	155.65	50.60	60.45
Price / Book	0.58	8.00	10.55	6.10
Net Income	-$7.96M	$23.81M	$3.60B	$331.73M
7 Day Performance	-28.33%	-1.36%	-1.69%	-1.47%
1 Month Performance	-55.09%	-1.43%	-0.56%	-2.75%
1 Year Performance	-89.03%	34.93%	19.23%	14.62%

HCW Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCWB HCW Biologics	3.5254 of 5 stars	$2.91 -13.1%	$30.00 +930.9%	-87.1%	$4.73M	$50K	N/A	40	News Coverage Gap Down
TVRD Tvardi Therapeutics	2.9447 of 5 stars	$2.93 -5.5%	$19.67 +571.2%	-89.1%	$27.48M	$7.14M	N/A	80	Positive News
PLRZ Polyrizon	0.8953 of 5 stars	$13.07 -5.0%	N/A	+65.4%	$27.19M	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	1.7528 of 5 stars	$0.65 +6.9%	$4.00 +511.0%	-66.8%	$26.74M	$14.97M	N/A	107	Analyst Upgrade
EVAX Evaxion A/S	2.5447 of 5 stars	$3.05 +0.7%	$11.00 +260.7%	+16.5%	$25.44M	$7.53M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCWB) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HCW Biologics (HCWB) Competitors

HCWB vs. TVRD, PLRZ, BRNS, EVAX, and VYNE

How does HCW Biologics compare to Tvardi Therapeutics?

Summary

How does HCW Biologics compare to Polyrizon?

Summary

How does HCW Biologics compare to Barinthus Biotherapeutics?

Summary

How does HCW Biologics compare to Evaxion A/S?

Summary

How does HCW Biologics compare to VYNE Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HCW Biologics (HCWB) Competitors

HCWB vs. TVRD, PLRZ, BRNS, EVAX, and VYNE

How does HCW Biologics compare to Tvardi Therapeutics?

Which has higher earnings & valuation, HCWB or TVRD?

Do analysts rate HCWB or TVRD?

Does the media prefer HCWB or TVRD?

Is HCWB or TVRD more profitable?

Do institutionals & insiders hold more shares of HCWB or TVRD?

Which has more risk & volatility, HCWB or TVRD?

Summary

How does HCW Biologics compare to Polyrizon?

Does the media prefer HCWB or PLRZ?

Is HCWB or PLRZ more profitable?

Do analysts recommend HCWB or PLRZ?

Do institutionals and insiders hold more shares of HCWB or PLRZ?

Which has higher valuation and earnings, HCWB or PLRZ?

Which has more volatility and risk, HCWB or PLRZ?

Summary

How does HCW Biologics compare to Barinthus Biotherapeutics?

Do institutionals and insiders believe in HCWB or BRNS?

Which has preferable valuation & earnings, HCWB or BRNS?

Do analysts recommend HCWB or BRNS?

Does the media prefer HCWB or BRNS?

Which has more risk & volatility, HCWB or BRNS?

Is HCWB or BRNS more profitable?

Summary

How does HCW Biologics compare to Evaxion A/S?

Does the media favor EVAX or HCWB?

Is EVAX or HCWB more profitable?

Do analysts rate EVAX or HCWB?

Which has more risk & volatility, EVAX or HCWB?

Do institutionals & insiders hold more shares of EVAX or HCWB?

Which has better valuation and earnings, EVAX or HCWB?

Summary

How does HCW Biologics compare to VYNE Therapeutics?

Does the media prefer HCWB or VYNE?

Do insiders and institutionals believe in HCWB or VYNE?

Which has more risk & volatility, HCWB or VYNE?

Do analysts prefer HCWB or VYNE?

Is HCWB or VYNE more profitable?

Which has higher valuation & earnings, HCWB or VYNE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools